Natco Pharma Ltd - Share Price
NATCOPHARM
Natco Pharma LtdFinancials
Natco Pharma LtdNews & Updates
Natco Pharma gets USFDA approval for Carfilzomib Vials ANDA in the US market
Jun 14,2021 05:08 PM
The parties have received final approval for 10mg and 60mg strengths of the product and tentative approval for 30mg strength of th
Natco Pharma gets USFDA approval for carfilzomib vials Jun 14,2021
Natco Pharma schedules board meeting Jun 08,2021
NATCO's marketing partner Breckenridge Pharma bags USFDA approval for Everolimus Tablets May 24,2021
NATCO Pharma begins phase-3 clinical trials of Molnupiravir capsules; Stock hits new all-time high May 24,2021
Centre to ramp-up Amphotericin-B production; Natco, Alembic, Gufic also bag license for anti-fungal drug May 24,2021
Meeting Type
Meeting Date
| Resolution Type | Description Of Resolution | IiAS Recommendation |
|---|
Peer Comparison
| Name | LTP | PE | Mar Cap | NP Qtr | Div. Yld | Sales Qtr | BV |
|---|
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Natco Pharma LtdSummary & Reports
No Company Summary found
Registered Office
Natco House,Road No 2 Banjara Hills,Hyderabad, Telangana,500033
Tell. : +91-040-23547532
Website : http://www.natcopharma.co.in
Email : investors@natcopharma.co.in
Registrar Office
12-10-167, Bharath Nagar, Hyderbad - 500018 INDIA
Tell. : +91-040-23818475/76/2
Website : www.vccilindia.com
Email : info@vccilindia.com
Reports by natco-pharma-ltd-share-price
Latest Release by natco-pharma-ltd-share-price
Result Express
Natco Pharma Ltd's Q2FY19 consolidated net profit rises 115.17% yoy to Rs181.60cr : Misses Estimates
Jun 15, 2021 08:45 AM
The company’s consolidated revenue stood at Rs543.50cr, up 27.37% yoy and 0.91% qoq.
Shareholding Snapshot
Loading ...
| Mar - 2021 | |
|---|---|
| Promoter | - |
| Foreign | 0.00% |
| Indian | 48.87% |
| Total Promoter | 48.87% |
| Non Promoter | - |
| Institutions | 32.49% |
| Non-Institutions | 18.65% |
| Total Non-Promoter | 51.13% |
| Custodian | 0.00% |
| Total | 100% |
Corporate Action
Purpose
Board Meeting
Exp. Date
26 Mar 2021
Annc. Date
26 Mar 2021
To acquire 0.96% stake in NATCO Pharma (Canada) Inc., after this acquisition NATCO Pharma (Canada) I... More
Purpose
Dividend
Annc. Date
11 Feb 2021
Effective. Date
22 Feb 2021
Divi. Type
Interim 3
Divi.(%)
50
Divi. Amt.
1
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on ... More
Purpose
Board Meeting
Exp. Date
11 Feb 2021
Annc. Date
03 Feb 2021
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is sched... More
